88E prepares for stimulation at Icewine
Shares in 88 Energy (ASX:88E) have spiked nearly 40% since the start of June, increasing from 5 cents to hit a high of 6.8 cents on Tuesday morning. The most recent rerating occurred under extremely high volumes, suggesting there may be some smart money behind the move as the company prepares to perform the stimulation at Project Icewine test on June 17.
This is also the highest level the company’s shares have traded at since September 2016 when they hit an intraday high of 6.2 cents. Hence, there could be some interest from technical analysts.
It should be noted share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.
Icewine is located onshore North Slope of Alaska, and the company has successfully completed the drilling campaign, as well as the stimulation design.
Perhaps giving investors further confidence was the fact that insights have been gained into the stress profile and pore pressure of the HRZ, which appears higher than previously expected. Management highlighted last week that this can have a direct effect on potentially higher flow rates.
This commentary appeared to contribute to the rerating as the company’s shares increased more than 10% from 5.3 cents on the previous day to close at 6 cents. This was under particularly high volumes in excess of 20 million shares, and on the following day 88E hit 6.5 cents with 37 million shares traded, the second highest volumes in the last six months.
By 2.30 PM on Tuesday nearly 40 million shares had been traded, suggesting the six-month record for the most shares traded in a day (41.5 million) set in December 2016 could be eclipsed. The intraday high of 6.8 cents represented an increase of 17.5% compared with the previous day’s close.
The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.
Not only is the stimulation procedure on track for commencement towards the end of this week/early next week, but production testing is also imminent with management forecasting late June/early July.
There are a number of variables in play that could result in the project being the catalyst for a significant rerating.
The next phase of the program will comprise the planned artificial stimulation and production testing which should resolve a number of current uncertainties, including whether complex artificial fracture systems can be created within the HRZ by the proposed stimulation.
These complex fracture systems are evident in the best performing shale plays as a result in maximised stimulation rock volume, directly impacting potential flow rates.
Similarly, while substantial work has been done on thermal maturity, the exact gas/oil ratio is difficult to predict prior to flow test, and this also has the potential to impact the value of the asset.
However, 88E appears to have all bases covered with management recently saying, “The company interprets that the vast majority of the HRZ sweet spot has been captured irrespective of any uncertainty due to the large acreage position”.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.